190 related articles for article (PubMed ID: 17287403)
1. What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics.
Gürlek A; Karavitaki N; Ansorge O; Wass JA
Eur J Endocrinol; 2007 Feb; 156(2):143-53. PubMed ID: 17287403
[TBL] [Abstract][Full Text] [Related]
2. Polysialylated neural cell adhesion molecules expressed in human pituitary tumors and related to extrasellar invasion.
Trouillas J; Daniel L; Guigard MP; Tong S; Gouvernet J; Jouanneau E; Jan M; Perrin G; Fischer G; Tabarin A; Rougon G; Figarella-Branger D
J Neurosurg; 2003 May; 98(5):1084-93. PubMed ID: 12744370
[TBL] [Abstract][Full Text] [Related]
3. Relationship between expression of vascular endothelial growth factor and the proliferation of prolactinomas.
Li N; Jiang Z
Clin Neurol Neurosurg; 2017 Feb; 153():102-106. PubMed ID: 28110235
[TBL] [Abstract][Full Text] [Related]
4. Prolactinomas express human heparin-binding secretory transforming gene (hst) protein product: marker of tumour invasiveness.
Shimon I; Hinton DR; Weiss MH; Melmed S
Clin Endocrinol (Oxf); 1998 Jan; 48(1):23-9. PubMed ID: 9509064
[TBL] [Abstract][Full Text] [Related]
5. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
[TBL] [Abstract][Full Text] [Related]
6. Angiogenesis in prolactinomas: regulation and relationship with tumour behaviour.
de la Torre NG; Turner HE; Wass JA
Pituitary; 2005; 8(1):17-23. PubMed ID: 16411064
[TBL] [Abstract][Full Text] [Related]
7. Angiogenesis in pituitary adenomas - relationship to endocrine function, treatment and outcome.
Turner HE; Nagy Z; Gatter KC; Esiri MM; Harris AL; Wass JA
J Endocrinol; 2000 May; 165(2):475-81. PubMed ID: 10810311
[TBL] [Abstract][Full Text] [Related]
8. PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes.
Cristina C; Díaz-Torga GS; Goya RG; Kakar SS; Perez-Millán MI; Passos VQ; Giannella-Neto D; Bronstein MD; Becu-Villalobos D
Mol Cancer; 2007 Jan; 6():4. PubMed ID: 17222350
[TBL] [Abstract][Full Text] [Related]
9. MiR-137's Tumor Suppression on Prolactinomas by Targeting MITF and Modulating Wnt Signaling Pathway.
Lei C; Jing G; Jichao W; Xiaohui L; Fang Q; Hua G; Yazhou M; Zhang Y
J Clin Endocrinol Metab; 2019 Dec; 104(12):6391-6402. PubMed ID: 31162548
[TBL] [Abstract][Full Text] [Related]
10. Thrombospondin-1 and transforming growth factor-β1 levels in prolactinoma and their clinical significance.
Jiang M; Mou CZ; Han T; Wang M; Yang W
J Int Med Res; 2012; 40(4):1284-94. PubMed ID: 22971480
[TBL] [Abstract][Full Text] [Related]
11. ras mutations in human prolactinomas and pituitary carcinomas.
Cai WY; Alexander JM; Hedley-Whyte ET; Scheithauer BW; Jameson JL; Zervas NT; Klibanski A
J Clin Endocrinol Metab; 1994 Jan; 78(1):89-93. PubMed ID: 8288721
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas.
Luque GM; Perez-Millán MI; Ornstein AM; Cristina C; Becu-Villalobos D
J Pharmacol Exp Ther; 2011 Jun; 337(3):766-74. PubMed ID: 21406548
[TBL] [Abstract][Full Text] [Related]
13. Pathogenesis of prolactinomas.
Spada A; Mantovani G; Lania A
Pituitary; 2005; 8(1):7-15. PubMed ID: 16411063
[TBL] [Abstract][Full Text] [Related]
14. Role of matrix metalloproteinase 9 in pituitary tumor behavior.
Turner HE; Nagy Z; Esiri MM; Harris AL; Wass JA
J Clin Endocrinol Metab; 2000 Aug; 85(8):2931-5. PubMed ID: 10946906
[TBL] [Abstract][Full Text] [Related]
15. Expression of Stem Cell Markers and Dopamine D2 Receptors in Human and Rat Prolactinomas.
Gao Z; Cai L; Lu J; Wang C; Li Q; Chen J; Song X; Chen X; Zhang L; Zheng W; Su Z
Med Sci Monit; 2017 Apr; 23():1827-1833. PubMed ID: 28411401
[TBL] [Abstract][Full Text] [Related]
16. PTTG and Ki-67 expression in pituitary adenomas.
Wierzbicka-Tutka I; Sokołowski G; Bałdys-Waligórska A; Adamek D; Radwańska E; Gołkowski F
Przegl Lek; 2016; 73(2):53-8. PubMed ID: 27197423
[TBL] [Abstract][Full Text] [Related]
17. A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors.
Wierinckx A; Auger C; Devauchelle P; Reynaud A; Chevallier P; Jan M; Perrin G; Fèvre-Montange M; Rey C; Figarella-Branger D; Raverot G; Belin MF; Lachuer J; Trouillas J
Endocr Relat Cancer; 2007 Sep; 14(3):887-900. PubMed ID: 17914117
[TBL] [Abstract][Full Text] [Related]
18. Combining Cadherin Expression with Molecular Markers Discriminates Invasiveness in Growth Hormone and Prolactin Pituitary Adenomas.
Chauvet N; Romanò N; Meunier AC; Galibert E; Fontanaud P; Mathieu MN; Osterstock G; Osterstock P; Baccino E; Rigau V; Loiseau H; Bouillot-Eimer S; Barlier A; Mollard P; Coutry N
J Neuroendocrinol; 2016 Feb; 28(2):12352. PubMed ID: 26686489
[TBL] [Abstract][Full Text] [Related]
19. Nuclear accumulation of e-cadherin correlates with loss of cytoplasmic membrane staining and invasion in pituitary adenomas.
Elston MS; Gill AJ; Conaglen JV; Clarkson A; Cook RJ; Little NS; Robinson BG; Clifton-Bligh RJ; McDonald KL
J Clin Endocrinol Metab; 2009 Apr; 94(4):1436-42. PubMed ID: 19158195
[TBL] [Abstract][Full Text] [Related]
20. Gene expression in prolactinomas: a systematic review.
Seltzer J; Scotton TC; Kang K; Zada G; Carmichael JD
Pituitary; 2016 Feb; 19(1):93-104. PubMed ID: 26238304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
